Clinical efficacy of FGLM-NH2+SSSR peptides eye drops for neurotrophic keratopathy in leprosy sequelae.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs071220053

Enrollment

Registered

2022-09-14

Start date

2022-10-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurotorophic keratopathy neurotrophic keratopathy, persistent epitherial defect, corneal stromal thinning

Interventions

In cases of neurotrophic keratopathy, FGLM-NH2+ SSSR instillation is instilled four times a day (mor ning, noon, evening, before bedtime). The amount of 1 time is 1 drop, and it continues for up to 3

E02.319.267.120.805 MeSH Unique ID: D 060433

Administrations, Ophthalmic

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with neurotrophic keratopathy in leprosy sanatoriums 2. Cases with written consent by informed consent 3. Those with corneal perception of less than 40 m m nylon yarn length by the Cochet-Bonnet corneal perceptometer 4. Persistent corneal epithelial defects and/or Corneal stromal thinning

Exclusion criteria

Exclusion criteria: 1. Hypersensitivity or history of eye drops 2. Those with treatment due to the infection in acute phase

Design outcomes

Primary

Measure	Time frame
Improvement of neuroparalytic keratopathy The patient is judged to have improved when one or more of the following two criteria are met. -Healing and reducing epithelial defects -Changes in corneal thickness in thin corneas	—

Secondary

Measure	Time frame
1. visual acuity 2. subjectve findings 3. time to complete healing for persistent epithelial defect	—

Contacts

Public ContactShoko Kondo

National Sanatrium Kikuchi Keifuen

shoko.kondo@gmail.com+81-96-248-1131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026